JP2010508847A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010508847A5 JP2010508847A5 JP2009536307A JP2009536307A JP2010508847A5 JP 2010508847 A5 JP2010508847 A5 JP 2010508847A5 JP 2009536307 A JP2009536307 A JP 2009536307A JP 2009536307 A JP2009536307 A JP 2009536307A JP 2010508847 A5 JP2010508847 A5 JP 2010508847A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tes7
- tumor
- carcinoma
- sarcoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 36
- 206010028980 Neoplasm Diseases 0.000 claims 30
- 201000011510 cancer Diseases 0.000 claims 20
- 206010024612 Lipoma Diseases 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- 230000001394 metastastic effect Effects 0.000 claims 11
- 206010061289 metastatic neoplasm Diseases 0.000 claims 11
- 208000003174 Brain Neoplasms Diseases 0.000 claims 8
- 206010009944 Colon cancer Diseases 0.000 claims 8
- 108060003951 Immunoglobulin Proteins 0.000 claims 8
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 8
- 206010038389 Renal cancer Diseases 0.000 claims 8
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 8
- 206010039491 Sarcoma Diseases 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 8
- 102000018358 immunoglobulin Human genes 0.000 claims 8
- 201000010982 kidney cancer Diseases 0.000 claims 8
- 150000007523 nucleic acids Chemical group 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 8
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 8
- 208000008732 thymoma Diseases 0.000 claims 8
- 208000005243 Chondrosarcoma Diseases 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 238000001514 detection method Methods 0.000 claims 6
- 239000003446 ligand Substances 0.000 claims 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 5
- 201000010881 cervical cancer Diseases 0.000 claims 5
- 230000003993 interaction Effects 0.000 claims 5
- 208000030507 AIDS Diseases 0.000 claims 4
- 208000001783 Adamantinoma Diseases 0.000 claims 4
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 claims 4
- 208000019838 Blood disease Diseases 0.000 claims 4
- 206010005949 Bone cancer Diseases 0.000 claims 4
- 208000018084 Bone neoplasm Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 208000001843 Carotid Body Tumor Diseases 0.000 claims 4
- 208000037211 Carotid body tumour Diseases 0.000 claims 4
- 201000009047 Chordoma Diseases 0.000 claims 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 4
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 4
- 206010014967 Ependymoma Diseases 0.000 claims 4
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 4
- 208000021309 Germ cell tumor Diseases 0.000 claims 4
- 208000009164 Islet Cell Adenoma Diseases 0.000 claims 4
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 208000000172 Medulloblastoma Diseases 0.000 claims 4
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 4
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 4
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 4
- 208000000035 Osteochondroma Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 4
- 206010033963 Parathyroid tumour Diseases 0.000 claims 4
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims 4
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 4
- 206010057644 Testis cancer Diseases 0.000 claims 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 4
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 4
- 230000000890 antigenic effect Effects 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 4
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 4
- 208000009060 clear cell adenocarcinoma Diseases 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 claims 4
- 201000011523 endocrine gland cancer Diseases 0.000 claims 4
- 230000003352 fibrogenic effect Effects 0.000 claims 4
- 210000000232 gallbladder Anatomy 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 201000010536 head and neck cancer Diseases 0.000 claims 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims 4
- 208000014951 hematologic disease Diseases 0.000 claims 4
- 208000018706 hematopoietic system disease Diseases 0.000 claims 4
- 208000006359 hepatoblastoma Diseases 0.000 claims 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 4
- 210000004408 hybridoma Anatomy 0.000 claims 4
- 201000010260 leiomyoma Diseases 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 206010024627 liposarcoma Diseases 0.000 claims 4
- 201000007270 liver cancer Diseases 0.000 claims 4
- 208000014018 liver neoplasm Diseases 0.000 claims 4
- 201000005202 lung cancer Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 230000003211 malignant effect Effects 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 206010027191 meningioma Diseases 0.000 claims 4
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 4
- 201000011519 neuroendocrine tumor Diseases 0.000 claims 4
- 201000008968 osteosarcoma Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 201000010279 papillary renal cell carcinoma Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000028591 pheochromocytoma Diseases 0.000 claims 4
- 208000010916 pituitary tumor Diseases 0.000 claims 4
- 201000002267 posterior uveal melanoma Diseases 0.000 claims 4
- 201000000849 skin cancer Diseases 0.000 claims 4
- 201000011096 spinal cancer Diseases 0.000 claims 4
- 208000014618 spinal cord cancer Diseases 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 206010042863 synovial sarcoma Diseases 0.000 claims 4
- 201000003120 testicular cancer Diseases 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 201000002510 thyroid cancer Diseases 0.000 claims 4
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 4
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 4
- 208000017997 tumor of parathyroid gland Diseases 0.000 claims 4
- 206010046766 uterine cancer Diseases 0.000 claims 4
- 208000008884 Aneurysmal Bone Cysts Diseases 0.000 claims 3
- 206010004593 Bile duct cancer Diseases 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 3
- 206010029260 Neuroblastoma Diseases 0.000 claims 3
- 201000009365 Thymic carcinoma Diseases 0.000 claims 3
- 208000008383 Wilms tumor Diseases 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 208000026900 bile duct neoplasm Diseases 0.000 claims 3
- 208000019065 cervical carcinoma Diseases 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 201000003914 endometrial carcinoma Diseases 0.000 claims 3
- 201000010103 fibrous dysplasia Diseases 0.000 claims 3
- 201000010175 gallbladder cancer Diseases 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 201000002529 islet cell tumor Diseases 0.000 claims 3
- 208000022013 kidney Wilms tumor Diseases 0.000 claims 3
- 239000003550 marker Substances 0.000 claims 3
- 201000008026 nephroblastoma Diseases 0.000 claims 3
- 208000007538 neurilemmoma Diseases 0.000 claims 3
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 claims 3
- 230000002093 peripheral effect Effects 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 208000013558 Developmental Bone disease Diseases 0.000 claims 2
- 206010072610 Skeletal dysplasia Diseases 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000008822 gestational choriocarcinoma Diseases 0.000 claims 2
- 208000030883 malignant astrocytoma Diseases 0.000 claims 2
- 206010039667 schwannoma Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 208000017234 Bone cyst Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 208000008524 alveolar soft part sarcoma Diseases 0.000 claims 1
- 230000003140 astrocytic effect Effects 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 230000035614 depigmentation Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000003619 fibrillary effect Effects 0.000 claims 1
- 208000003884 gestational trophoblastic disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 201000009500 myxoid chondrosarcoma Diseases 0.000 claims 1
- 210000003757 neuroblast Anatomy 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 201000004396 peripheral nerve schwannoma Diseases 0.000 claims 1
- 208000028528 solitary bone cyst Diseases 0.000 claims 1
- 208000017572 squamous cell neoplasm Diseases 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85811306P | 2006-11-08 | 2006-11-08 | |
| US60/858,113 | 2006-11-08 | ||
| US99388207P | 2007-09-14 | 2007-09-14 | |
| US60/993,882 | 2007-09-14 | ||
| PCT/US2007/023620 WO2008066691A2 (en) | 2006-11-08 | 2007-11-08 | Tes7 and antibodies that bind thereto |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010508847A JP2010508847A (ja) | 2010-03-25 |
| JP2010508847A5 true JP2010508847A5 (https=) | 2011-11-04 |
| JP5601836B2 JP5601836B2 (ja) | 2014-10-08 |
Family
ID=39468449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009536307A Expired - Fee Related JP5601836B2 (ja) | 2006-11-08 | 2007-11-08 | Ｔｅｓ７およびｔｅｓ７に結合する抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7718774B2 (https=) |
| EP (1) | EP2094307A4 (https=) |
| JP (1) | JP5601836B2 (https=) |
| AU (1) | AU2007325872B2 (https=) |
| CA (1) | CA2668800A1 (https=) |
| IL (1) | IL198592A (https=) |
| WO (1) | WO2008066691A2 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100028256A1 (en) * | 2006-11-09 | 2010-02-04 | St Croix Brad | Differential gene expression in physiological and pathological angiogenesis |
| US20100203035A1 (en) * | 2007-02-14 | 2010-08-12 | Kwon Eugene D | B7-h3 in cancer |
| ES2589912T3 (es) | 2008-04-02 | 2016-11-17 | Macrogenics, Inc. | Anticuerpos específicos para el complejo BCR y procedimientos de uso de los mismos |
| US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
| CA2731686C (en) | 2008-07-25 | 2020-04-07 | Institute For Research In Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
| PL2350128T3 (pl) | 2008-10-22 | 2015-03-31 | Inst Res Biomedicine | Sposoby wytwarzania przeciwciał z komórek plazmatycznych |
| DK2786762T3 (da) | 2008-12-19 | 2019-05-06 | Macrogenics Inc | Kovalente diabodies og anvendelser deraf |
| TWI404931B (zh) * | 2009-02-20 | 2013-08-11 | 財團法人國家同步輻射研究中心 | 癌化生物樣本之檢測方法及其使用之檢驗試劑 |
| CA2729593A1 (en) * | 2009-02-20 | 2010-08-26 | John Wayne Cancer Institute | B7-h3 as a biomarker for diagnosing the progression and early lymph node metastasis of cancer |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| WO2012004410A1 (en) * | 2010-07-09 | 2012-01-12 | Oslo Universitetssykehus Hf | B7-h3 antagonists and taxanes |
| AU2011286024B2 (en) | 2010-08-02 | 2014-08-07 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| KR102125672B1 (ko) | 2011-04-25 | 2020-06-23 | 다이이찌 산쿄 가부시키가이샤 | 항 ｂ７-ｈ３항체 |
| WO2012147713A1 (ja) | 2011-04-25 | 2012-11-01 | 第一三共株式会社 | 抗ｂ７－ｈ３抗体 |
| BR112013029892A2 (pt) | 2011-05-21 | 2016-12-20 | Macrogenics Inc | polipeptídeo, molécula de ligação a antígeno, diacorpo e uso de uma porção polipeptídica de uma proteína de ligação a soro desimunizada |
| AU2011373387B2 (en) | 2011-07-18 | 2017-06-29 | Institute For Research In Biomedicine | Neutralizing anti-influenza A virus antibodies and uses thereof |
| ES2702315T3 (es) | 2012-08-24 | 2019-02-28 | Univ California | Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| SI3052192T1 (sl) | 2013-10-02 | 2020-11-30 | Medimmune, Llc | Nevtralizarijoča protitelesa proti-influenci A in njihove uporabe |
| KR20160135190A (ko) | 2014-02-14 | 2016-11-25 | 앤드류 에스. 카이 | 혈관형성 암의 치료를 위한 개선된 방법 |
| MX392761B (es) | 2014-07-15 | 2025-03-21 | Medimmune Llc | Anticuerpos anti-influenza b neutralizantes y usos de los mismos. |
| HUE056407T2 (hu) | 2015-06-01 | 2022-02-28 | Medimmune Llc | Neutralizáló influenzaellenes kötõmolekulák és alkalmazásaik |
| BR112018006817A2 (pt) | 2015-10-08 | 2018-10-23 | Macrogenics Inc | método de tratamento do câncer |
| SG11201805001UA (en) | 2016-01-13 | 2018-07-30 | Medimmune Llc | Method of treating influenza a |
| GEP20227398B (en) | 2016-04-15 | 2022-07-25 | Macrogenics Inc | Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof |
| AU2017279550A1 (en) * | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-B7-H3 antibodies and antibody drug conjugates |
| TWI767915B (zh) | 2016-06-27 | 2022-06-21 | 加州大學董事會 | Ror-1與btk拮抗劑的組合 |
| MX2019011117A (es) | 2017-03-31 | 2019-11-05 | Jiangsu Hengrui Medicine Co | Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. |
| CA3114474A1 (en) | 2018-09-30 | 2020-04-02 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof |
| CN119080930A (zh) * | 2019-07-11 | 2024-12-06 | 纪念斯隆凯特琳癌症中心 | Dll3靶向抗体及其用途 |
| US20240118284A1 (en) * | 2019-10-18 | 2024-04-11 | The Regents Of The University Of California | Compositions and methods for detecting plxdc1 and plxcd2 in human tissues |
| US12590298B2 (en) | 2019-10-18 | 2026-03-31 | The Regents Of The University Of California | Ex vivo tumor angiogenesis model |
| KR20220087497A (ko) | 2019-10-18 | 2022-06-24 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | 병원성 혈관을 표적화하기 위한 화합물 및 방법 |
| AU2020400221A1 (en) * | 2019-12-13 | 2022-05-19 | Harbour Biomed (Shanghai) Co., Ltd. | Anti-TSLP antibody and uses thereof |
| EP4257154A4 (en) | 2021-02-09 | 2026-04-22 | Medilink Therapeutics Suzhou Co Ltd | CONJUGATED WITH A BIOACTIVE SUBSTANCE, ITS PREPARATION PROCESS AND ITS USE |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3862925A (en) | 1973-07-05 | 1975-01-28 | American Home Prod | Preparation of somatotropin release inhibiting factor and intermediates therefor |
| US3842067A (en) | 1973-07-27 | 1974-10-15 | American Home Prod | Synthesis of(des-asn5)-srif and intermediates |
| JPS5726506B2 (https=) | 1974-03-08 | 1982-06-04 | ||
| US4105603A (en) | 1977-03-28 | 1978-08-08 | The Salk Institute For Biological Studies | Peptides which effect release of hormones |
| USRE30548E (en) | 1979-08-31 | 1981-03-17 | The Salk Institute For Biological Studies | Peptides which effect release of hormones |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5552391A (en) | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
| AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
| US5532159A (en) | 1994-04-01 | 1996-07-02 | The Ohio State University | Monoclonal antibody to canine placental oncofetal protein for detecting cancer |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| AU1672097A (en) | 1996-02-15 | 1997-09-02 | Chugai Seiyaku Kabushiki Kaisha | Monoclonal antibody that recognizes antigens present on the surface of endothelial cell of tumor vessel |
| WO2000068266A1 (en) | 1999-05-11 | 2000-11-16 | Eli Lilly And Company | Amyloid precursor protein protease and related nucleic acid compounds |
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| US6429303B1 (en) | 1999-09-03 | 2002-08-06 | Curagen Corporation | Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same |
| US6406840B1 (en) | 1999-12-17 | 2002-06-18 | Biomosaic Systems, Inc. | Cell arrays and the uses thereof |
| US20060154313A1 (en) | 2000-04-13 | 2006-07-13 | Immunex Corporation | Human B7 polypeptide B7-H3A |
| WO2001089567A1 (en) | 2000-05-22 | 2001-11-29 | Idec Pharmaceuticals Corporation | Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens |
| US6965018B2 (en) | 2000-06-06 | 2005-11-15 | Bristol-Myers Squibb Company | Antibodies directed to B7-related polypeptide, BSL-2 |
| US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
| US6891030B2 (en) | 2000-07-27 | 2005-05-10 | Mayo Foundation For Medical Education And Research | T-cell immunoregulatory molecule |
| WO2002022683A1 (fr) | 2000-09-12 | 2002-03-21 | Kirin Beer Kabushiki Kaisha | Nouvelle membrane a paroi cellulaire dendritique et son utilisation |
| US20030134283A1 (en) | 2000-10-03 | 2003-07-17 | Peterson David P. | Genes regulated in dendritic cell differentiation |
| US20070015144A9 (en) | 2001-05-25 | 2007-01-18 | Genset, S.A. | Human cDNAs and proteins and uses thereof |
| WO2002097046A2 (en) | 2001-05-25 | 2002-12-05 | Amgen, Inc. | B7 related protein-2 molecules and uses thereof |
| EP1390497A2 (en) | 2001-05-25 | 2004-02-25 | Genset | Human cdnas and proteins and uses thereof |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| EP1423402A4 (en) | 2001-08-02 | 2006-07-05 | Lilly Co Eli | NOVEL ANALOGUES OF POLYPEPTIDES AND HYBRID PROTEINS AND METHODS OF USE |
| US20040162236A1 (en) | 2002-04-01 | 2004-08-19 | John Alsobrook | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| ATE488530T1 (de) | 2002-06-19 | 2010-12-15 | Raven Biotechnologies Inc | Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel |
| EP2365004B1 (en) | 2002-06-21 | 2016-01-06 | Johns Hopkins University School of Medicine | Membrane associated tumor endothelium markers |
| WO2004007527A2 (en) | 2002-07-11 | 2004-01-22 | Incyte Corporation | Secreted proteins |
| WO2004023973A2 (en) | 2002-09-12 | 2004-03-25 | Incyte Corporation | Molecules for diagnostics and therapeutics |
| CA3007908A1 (en) | 2003-03-07 | 2005-04-14 | Dsm Ip Assets B.V. | Hydrolases, nucleic acids encoding them and methods for making and using them |
| US20050002935A1 (en) | 2003-04-17 | 2005-01-06 | Vincent Ling | Use of B7-H3 as an immunoregulatory agent |
| US20050090440A1 (en) | 2003-04-28 | 2005-04-28 | Krissansen Geoffrey W. | Tumour treating combinations, compositions and methods |
| US20050070474A1 (en) | 2003-04-28 | 2005-03-31 | Krissansen Geoffrey Wayne | Methods of treatment and compositions therefor |
| WO2005017163A2 (en) | 2003-08-15 | 2005-02-24 | Imperial College Innovations Limited | Phenotypic knockout of cell-surface proteins |
| DK1773884T3 (da) * | 2004-08-03 | 2012-05-21 | Innate Pharma | Terapeutiske og diagnostiske fremgangsmåder og sammensætninger til targeting af 4ig-b7-h3 og dets tilsvarende nk-celle-receptor |
| CA2601472A1 (en) | 2005-03-08 | 2006-09-14 | Verenium Corporation | Hydrolases, nucleic acids encoding them and methods for improving paper strength |
| CA2611861C (en) | 2005-06-08 | 2017-11-28 | The Brigham And Women's Hospital, Inc. | Methods and compositions for the treatment of persistent infections |
| MX2008007292A (es) | 2005-12-08 | 2008-10-17 | Univ Louisville Res Found | Composiciones inmunoestimuladoras y metodos. |
| NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
-
2007
- 2007-11-08 AU AU2007325872A patent/AU2007325872B2/en not_active Ceased
- 2007-11-08 JP JP2009536307A patent/JP5601836B2/ja not_active Expired - Fee Related
- 2007-11-08 US US11/937,470 patent/US7718774B2/en not_active Expired - Fee Related
- 2007-11-08 WO PCT/US2007/023620 patent/WO2008066691A2/en not_active Ceased
- 2007-11-08 CA CA002668800A patent/CA2668800A1/en not_active Abandoned
- 2007-11-08 EP EP07870862.5A patent/EP2094307A4/en not_active Withdrawn
-
2009
- 2009-05-06 IL IL198592A patent/IL198592A/en active IP Right Grant
-
2010
- 2010-03-16 US US12/724,564 patent/US8216570B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010508847A5 (https=) | ||
| JP2010110329A5 (https=) | ||
| JP2005532050A5 (https=) | ||
| JP2008529494A5 (https=) | ||
| JP2008532488A5 (https=) | ||
| JP2011130770A5 (https=) | ||
| TWI779386B (zh) | 抗trop2抗體及其生產方法、及抗trop2抗體-藥物結合物 | |
| JP2022017292A (ja) | 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体 | |
| HRP20200591T1 (hr) | Protutijela specifična za klaudin 6 (cldn6) | |
| JPWO2020122034A1 (ja) | 抗体−薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ | |
| CN118955716A (zh) | 结合cd137的单结构域抗体 | |
| JP2023547323A5 (https=) | ||
| CN115698072B (zh) | 抗gpc3抗体，抗gpc3嵌合抗原受体和gpc3/cd3双特异性抗体 | |
| JP2005514409A (ja) | Ｍｕｃ１８抗原に対する抗体の使用 | |
| JP2004534020A5 (https=) | ||
| JP2005514425A (ja) | Ｍｕｃ１８抗原に対する抗体 | |
| JP2008508858A5 (https=) | ||
| BR112021001750A2 (pt) | composição farmacêutica | |
| JP2005516965A (ja) | 抗ｍｕｃ１８抗体を使用する方法 | |
| JP2008529497A5 (https=) | ||
| JP2012502938A5 (https=) | ||
| JP2010535713A5 (https=) | ||
| WO2007114496A1 (ja) | 新規抗ｃｄ９８抗体 | |
| JP2010531140A5 (https=) | ||
| JP2005505256A5 (https=) |